Dementia screening, biomarkers and protein misfolding

References

• Venneti S. Prion diseases. Clin Lab Med 2010; 30:293 - 309
   PubMed Web of Science ®Google Scholar
• Sharma S, Mukherjee M, Kedage V, Muttigi MS, Rao A, Rao S. Sporadic Creutzfeldt-Jakob disease—a review. Int J Neurosci 2009; 119:1981 - 1994
   PubMed Web of Science ®Google Scholar
• Tarawneh R, Galvin JE. Distinguishing Lewy body dementias from Alzheimer's disease. Expert Rev Neurother 2007; 7:1499 - 1516
   PubMedGoogle Scholar
• Tan JM, Wong ES, Lim KL. Protein misfolding and aggregation in Parkinson's disease. Antioxid Redox Signal 2009; 11:2119 - 2134
   PubMed Web of Science ®Google Scholar
• Bugiani O. The many ways to frontotemporal degeneration and beyond. Neurol Sci 2007; 28:241 - 244
   PubMed Web of Science ®Google Scholar
• Cairns NJ, Ghoshal N. FUS: A new actor on the frontotemporal lobar degeneration stage. Neurology 2010; 74:354 - 356
   PubMed Web of Science ®Google Scholar
• Alzheimer Association. Facts and Figures 2010; 11/15/10 http://www.alz.org
   Google Scholar
• Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66:1447 - 1455
   PubMed Web of Science ®Google Scholar
• Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, et al. Alzheimer's Disease Neuroimaging Initiative: Serial MRI and CSF biomarkers in normal aging, MCI and AD. Neurology 2010; 75:143 - 151
   PubMed Web of Science ®Google Scholar
• Funke SA, Birkmann E, Willbold D. Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?. Curr Alzheimer Res 2009; 6:285 - 289
   PubMed Web of Science ®Google Scholar
• Galvin JE. Alzheimer disease: Understanding the challenges, improving the outcome. App Neurol 2007; 3 - 13
   Google Scholar
• Galvin JE. Alzheimer's disease: Diagnosis and treatment across the spectrum. App Neurol 2005; 1:1 - 16
   Google Scholar
• Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009; 461:916 - 922
   PubMed Web of Science ®Google Scholar
• Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010; 223:334 - 346
   PubMed Web of Science ®Google Scholar
• Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008; 4:38 - 48
   PubMed Web of Science ®Google Scholar
• Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009; 30:1026 - 1036
   PubMed Web of Science ®Google Scholar
• Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Storandt M, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol 2005; 62:758 - 765
   PubMed Web of Science ®Google Scholar
• Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67:446 - 452
   PubMed Web of Science ®Google Scholar
• Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66:1469 - 1475
   PubMed Web of Science ®Google Scholar
• De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67:949 - 956
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6:131 - 144
   PubMed Web of Science ®Google Scholar
• Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302:385 - 393
   PubMed Web of Science ®Google Scholar
• Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1:371 - 380
   PubMed Web of Science ®Google Scholar
• Fagan A, Mintun M, Mach R, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and CSF Abeta42 in humans. Ann Neurol 2006; 59:512 - 519
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9:119 - 128
   PubMed Web of Science ®Google Scholar
• Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403 - 413
   PubMed Web of Science ®Google Scholar
• Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64:343 - 349
   PubMed Web of Science ®Google Scholar
• Hampel H, Broich K. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. J Nutr Health Aging 2009; 13:373 - 375
   PubMed Web of Science ®Google Scholar
• Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimers Dis 2010; 610 - 613
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939 - 944
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734 - 746
   PubMed Web of Science ®Google Scholar
• Urbanelli L, Magini A, Ciccarone V, Trivelli F, Polidoro M, Tancini B, et al. New perspectives for the diagnosis of Alzheimer's disease. Recent Pat CNS Drug Discov 2009; 4:160 - 181
   PubMedGoogle Scholar
• Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ. Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis 2010; 7:131 - 135
   PubMed Web of Science ®Google Scholar
• Brys M, Glodzik-Sobanska L, Switalski R, Rich K, Pirraglia E, Mosconi L, et al. MRI Improves CSF biomarkers in the early detection of Alzheimer's disease. J Alz Dis 2008; 16:351 - 362
   Web of Science ®Google Scholar
• Wright CF, Hall A, Matthews FE, Brayne C. Biomarkers, dementia and public health. Ann NY Acad Sci 2009; 1180:11 - 19
   PubMed Web of Science ®Google Scholar
• HR2959: Accountable Care Promotion Act of 2009 11/15/10 www.govtrack.us/congress/bill.xpd?bill=h111-2959
   Google Scholar
• Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306 - 319
   PubMed Web of Science ®Google Scholar
• Haldenwanger A, Eling P, Kastrup A, Hildebrandt H. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI and Alzheimer's disease. J Alzheimers Dis 2010; 22:971 - 980
   PubMed Web of Science ®Google Scholar
• Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009; 66:1254 - 1259
   PubMed Web of Science ®Google Scholar
• Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC. Relationship of dementia screening tests with biomarkers of Alzheimer's Disease. Brain 2010; 133:3290 - 3300
   PubMed Web of Science ®Google Scholar
• Galvin JE, Roe C, Coats M, Powlishta KK, Muich SJ, Grant E, et al. The AD8: A brief informant interview to detect dementia. Neurology 2005; 65:559 - 564
   PubMed Web of Science ®Google Scholar
• Galvin JE, Roe CM, Xiong C, Morris JC. The validity and reliability of the AD8 informant interview for dementia. Neurology 2006; 67:1942 - 1948
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. Mini-mental State: A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 1975; 12:189 - 198
   PubMed Web of Science ®Google Scholar
• Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983; 140:734 - 739
   PubMed Web of Science ®Google Scholar
• Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993; 43:2412 - 2414
   PubMed Web of Science ®Google Scholar
• Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46:2740 - 2754
   PubMed Web of Science ®Google Scholar
• Glodzik-Sobanska L, Pirraglia E, Brys M, De Santi S, Mosconi L, Rich KE, et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 2009; 30:672 - 681
   PubMed Web of Science ®Google Scholar
• Tarawneh R, Galvin JE. Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clinic Geriatr Med 2010; 26:125 - 147
   PubMed Web of Science ®Google Scholar